References
- Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr 2006; 18: 64–70
- Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25: 1196–1204
- Sabharwal V, Marchant CD. Fluoroquinolones use in children. Pediatr Infect Dis J 2006; 25: 257–8
- Kuban R. Safety and efficacy of ciprofloxacin in paediatric patients. Review Infection 1993; 21: 413–21
- Ahmed NU, Khan NZ, Saha SK, Chowdury MA, Muslima H, Law P, et al. Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development. Pediatr Infect Dis J 2006; 25: 1137–41
- Dan M, Keynan O, Feldbrin Z, Poch F. Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens. Diagn Microbiol Infect Dis 2004; 48: 283–6
- Burkhardt O, Kohnlein T, Pap T, Welte T. Recurrent tendinitis after treatment with 2 different fluoroquinolones. Scand J Infect Dis. 2004; 36: 315–6
- Harrell RM. Fluoroquinolone-induced tendinopathy: what we do now?. South Med J 1999; 92: 622–5
- Williams RJ III, Attia E, Wickiewicz TL, Hannafin JA. The effect of ciprofloxacin on tendon, paratendon, and capsular fibroblast metabolism. Am J Sports Med 2000; 28: 364–9
- Iannini PB, Kubin R, Reiter C, Tillotson G. Reassuring safety profile of moxifloxacin. Clin Infect Dis 2001; 32: 1112–4
- Bailey RR, Natale R, Linton AL. Nalidixic acid arthralgia. Can Med Assoc J 1972; 107: 604–7